Obtusifolin mitigates CCl4-induced inflammation and liver fibrosis by modulating the ROCK2/ Cofilin-1 / NFκB pathway
European Journal of Pharmacology · 2026
DOI: 10.1016/j.ejphar.2025.178479 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Pharmacology, 2026. Verfasst von Suriya Panneerselvam und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Applied Biology, CSIR-Indian Institute of Chemical Technology, Hyderabad, 500 007, Telangana, India; Academy of Scientific and Innovati…. Hauptthemen laut MEDLINE: NF-kappa B, Liver Cirrhosis, rho-Associated Kinases, Anthraquinones. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 46 Literaturangaben. Gefördert von: Council of Scientific and Industrial Research, India.
Abstract (Originalsprache)
Liver fibrosis is a progressive clinical condition characterised by an abnormal accumulation of extracellular matrix (ECM) components, which are predominantly generated by activated hepatic stellate cells (HSCs) and other fibrogenic cells. This process leads to liver stiffness, which can progress to cirrhosis, an irreversible condition, and ultimately result in liver failure. Obtusifolin (OBT), an anthraquinone derivative isolated from the seeds of Senna obtusifolia, is known for its potent anti-inflammatory and antioxidant properties. The present study evaluated the anti-fibrotic efficacy of OBT using in vitro models, including TGFβ-induced differentiation in HUCLS, HSC-LX2, and HHSECs, and an in vivo CCl4-induced liver fibrosis model in mice. The in vitro results demonstrated that OBT significantly suppressed the TGFβ-induced upregulation of fibrotic markers at both mRNA and protein levels. In vivo, findings showed that CCl4 treatment caused significant increases in serum liver function markers, inflammatory cell infiltration, collagen deposition, and septal fibrosis in liver tissues. In contrast, OBT treatment attenuated these pathological changes in a dose-dependent manner. Furthermore, assays on oxidative stress indicators revealed that OBT significantly reduced oxidative stress markers and enhanced antioxidant levels. Gene and protein expression analyses showed that OBT suppressed the CCl4-induced elevation of inflammatory cytokines, chemokines, and fibrotic markers compared to the CCl4 control group. Mechanistic studies demonstrated that CCl4 administration activated the ROCK2/p-cofilin-1/pNFκB signaling pathway, whereas OBT treatment significantly modulated these molecular pathways. OBT alleviates liver inflammation and fibrosis by inhibiting oxidative stress, collagen accumulation, and the ROCK2/NFκB pathway, highlighting its potential as a therapeutic candidate for liver fibrosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Applied Biology, CSIR-Indian Institute of Chemical Technology, Hyderabad, 500 007, Telangana, India; Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, 201002, India.
- Department of Applied Biology, CSIR-Indian Institute of Chemical Technology, Hyderabad, 500 007, Telangana, India; Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, 201002, India. Electronic address: bal…
Förderung
- Council of Scientific and Industrial Research, India
Zitieren
APA
Panneerselvam, S., Sharma, N., & Andugulapati, S. B. (2026). Obtusifolin mitigates CCl4-induced inflammation and liver fibrosis by modulating the ROCK2/ Cofilin-1 / NFκB pathway. European Journal of Pharmacology. https://doi.org/10.1016/j.ejphar.2025.178479
Vancouver
Panneerselvam S, Sharma N, Andugulapati SB. Obtusifolin mitigates CCl4-induced inflammation and liver fibrosis by modulating the ROCK2/ Cofilin-1 / NFκB pathway. European Journal of Pharmacology. 2026. doi:10.1016/j.ejphar.2025.178479
BibTeX
@article{Panneerselvam2026,
author = {Panneerselvam, Suriya and Sharma, Nidhi and Andugulapati, Sai Balaji},
title = {Obtusifolin mitigates CCl4-induced inflammation and liver fibrosis by modulating the ROCK2/ Cofilin-1 / NFκB pathway},
journal = {European Journal of Pharmacology},
year = {2026},
doi = {10.1016/j.ejphar.2025.178479}
}
EUVIMED